Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 14/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16402907 | 0.87 | HTT (0.49) | HTTLMNAKMT2A | |
| SCHEMBL1040435 | 0.86 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL513388 | 0.86 | HTT (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1041283 | 0.86 | HTT (0.48) | HTTLMNAKMT2A | |
| SCHEMBL16914028 | 0.85 | TLR2 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL961730 | 0.84 | HTT (0.46) | HTTLMNAKMT2A | |
| SCHEMBL1616767 | 0.83 | ALDH1A1 (0.49) | LMNAKMT2A | |
| SCHEMBL10257666 | 0.83 | HTT (0.45) | HTTLMNAKMT2A | |
| SCHEMBL962880 | 0.83 | HTT (0.45) | HTTLMNAKMT2A | |
| SCHEMBL511516 | 0.83 | LMNA (0.45) | HTTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009087127-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009076337-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-2019093-A1 | UREA TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008138753-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | SMN1; SMN2, FUS, SYNCRIP | PSEN1 187/4885PSEN2 42/4885APH1B 774/4885 |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | PSEN1 2/4885PSEN2 6/4885APH1B 8/4885 |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | PSEN1 2/4885PSEN2 7/4885APH1B 4/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | PSEN1 7/4885PSEN2 6/4885APH1B 14/4885 |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | APP, BACE1, BACE2 | PSEN1 7/4885PSEN2 13/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.